Home › Trials › NCT05933876

Evaluating the effects of radiotherapy on patients with oligometastatic cancer

Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project

Observational Institut Investigacio Sanitaria Pere Virgili · NCT05933876

This study is testing how well Stereotactic Ablative Radiotherapy (SABR) works for people with oligometastatic cancer to see if it can help them live longer and feel better.

Quick facts

Study typeObservational
Enrollment2000 (estimated)
Ages18 Years and up
SexAll
SponsorInstitut Investigacio Sanitaria Pere Virgili Academic / other
Locations21 sites (Albacete, Albacete and 20 other locations)
Trial IDNCT05933876 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the impact of Stereotactic ABlative Radiotherapy (SABR) on patients with oligometastatic cancer, which is characterized by a limited number of metastases. By collecting clinical data, medical images, and biological samples from multiple centers, the study seeks to identify patient profiles that respond favorably to SABR. The research will utilize artificial intelligence to analyze this data and predict which patients are most likely to benefit from the treatment, ultimately aiming to improve survival rates and quality of life for these patients.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed metastatic breast, prostate, lung, or colorectal cancer and up to five metastases.

Not a fit: Patients with non-melanoma skin cancer, previous radiotherapy in the same area, or those with vascular collagen disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to personalized treatment strategies that significantly enhance survival rates for patients with oligometastatic cancer.

How similar studies have performed: While there have been few studies on SABR for oligometastatic cancer, the approach of using multi-omics data and artificial intelligence to personalize treatment is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.
* 18 years old or older.
* Up to five metastases located in the bone, lung, node, liver or brain.
* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.

Exclusion Criteria:

* Non-melanoma skin cancer.
* Previous radiotherapy in the same anatomic location.
* Presence of vascular collagen disease.
* Pregnancy or lactation at the time of inclusion.

Where this trial is running

Albacete, Albacete and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions MetastasisMetastatic Breast CancerMetastatic Prostate CancerMetastatic Colorectal CancerMetastatic Lung CancerRadiosurgeryMetabolomicsRadiomics
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.